PreveCeutical Medical (CSE: PREV; OTCQB: PRVCF; FSE: 18H0) has appointed Raj S. Pruthi, MD, MHA, FACS, to its board of directors (BOD).
Dr. Pruthi currently serves as CMO of Relmada Therapeutics. An accomplished physician-scientist and executive with more than 20 years of experience spanning academic medicine, global pharmaceutical leadership, and biotechnology innovation, he will contribute to shaping PreveCeutical’s clinical development strategy and advancing key initiatives.
In a statement, Stephen Van Deventer, chairman and CEO of PreveCeutical, commented, “We are very pleased to welcome Dr. Pruthi to our board. His extensive experience in clinical development, regulatory strategy, and leadership will be invaluable as we continue to advance our pipeline. His expertise strengthens our ability to deliver innovative therapies and achieve meaningful progress across our programs.”
